697305-73-0

Basic information

• Product Name: Benzenemethanamine, 5-amino-2-fluoro-N,N-dimethyl- (9CI)
• Synonyms: Benzenemethanamine, 5-amino-2-fluoro-N,N-dimethyl- (9CI)
• CAS NO: 697305-73-0
• Molecular Formula: C9H13FN2
• Molecular Weight: 168.2113232
• Product Categories: AMINETERTIARY
• Mol File: 697305-73-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenemethanamine, 5-amino-2-fluoro-N,N-dimethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 5-amino-2-fluoro-N,N-dimethyl- (9CI)(697305-73-0)
• EPA Substance Registry System: Benzenemethanamine, 5-amino-2-fluoro-N,N-dimethyl- (9CI)(697305-73-0)

Safety Data

• Hazardous Substances Data: 697305-73-0(Hazardous Substances Data)

Upstream product

• 697305-63-8 1-(2-fluoro-5-nitrophenyl)-N,N-dimethylmethanamine 
• 454-15-9 2-fluoro-5-nitrobenzyl bromide 
• 455-88-9 5-nitro-2-fluorotoluene 

Relevant articles and documents

DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. The present invention discloses the unexpected utility of compounds that inhibit cKIT kinase across a broad range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in individual, refractory GIST patients. Also unexpected is the utility of compounds of the present invention to inhibit the problematic exon 17 D816V c-KIT mutation, for which there is currently no effective therapy.

Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.